Mesoblast Limited reported a widened loss of US$102.14 million for the fiscal year ended June 30, 2025, with a narrowed net loss per share of 8.46 US cents. Annual total revenues from cell therapy products reached US$17.2 million, up 191% from the prior year, driven by the successful launch of Ryoncil in the final quarter.

Following the news, MESO’s stock closed Thursday’s regular trading at $15.95, down 1.05%, and dropped further by 10.97% in after-hours trading. For more earnings news and updates, visit rttnews.com.

Read more at Nasdaq: Mesoblast FY Loss Widens; Stock Down